- Home
- AMLX
as of 12-26-2025 4:00pm EST
$12.33
+$0.08
+0.65%
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.3B | IPO Year: | 2022 |
| Target Price: | $17.43 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.60 - $16.96 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | -77.06% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered AMLX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 73.97%
73.97%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Amylyx Pharmaceuticals Inc. (AMLX)
Firestone Karen
Buy
Director
AMLX Dec 23, 2025
Avg Cost/Share
$12.45
Shares
8,100
Total Value
$100,845.00
Owned After
63,100
SEC Form 4
Bedrosian Camille L
Sell
Chief Medical Officer
AMLX Dec 1, 2025
Avg Cost/Share
$14.35
Shares
6,580
Total Value
$94,418.39
Owned After
175,756
SEC Form 4
Cohen Joshua B
Sell
Co-Chief Executive Officer
AMLX Sep 30, 2025
Avg Cost/Share
$14.67
Shares
29,933
Total Value
$429,468.84
Owned After
3,325,547
Mazzariello Gina
Sell
Chief Legal Officer
AMLX Sep 30, 2025
Avg Cost/Share
$14.58
Shares
8,828
Total Value
$128,668.98
Owned After
148,141
SEC Form 4
Klee Justin B.
Sell
Co-Chief Executive Officer
AMLX Sep 30, 2025
Avg Cost/Share
$14.69
Shares
29,975
Total Value
$430,952.12
Owned After
3,325,501
Bedrosian Camille L
Sell
Chief Medical Officer
AMLX Sep 30, 2025
Avg Cost/Share
$14.58
Shares
12,039
Total Value
$175,517.78
Owned After
175,756
SEC Form 4
FRATES JAMES M
Sell
Chief Financial Officer
AMLX Sep 30, 2025
Avg Cost/Share
$14.65
Shares
10,558
Total Value
$154,650.42
Owned After
280,430
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Firestone Karen | AMLX | Director | Dec 23, 2025 | Buy | $12.45 | 8,100 | $100,845.00 | 63,100 | |
| Bedrosian Camille L | AMLX | Chief Medical Officer | Dec 1, 2025 | Sell | $14.35 | 6,580 | $94,418.39 | 175,756 | |
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Sep 30, 2025 | Sell | $14.67 | 29,933 | $429,468.84 | 3,325,547 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Sep 30, 2025 | Sell | $14.58 | 8,828 | $128,668.98 | 148,141 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Sep 30, 2025 | Sell | $14.69 | 29,975 | $430,952.12 | 3,325,501 | |
| Bedrosian Camille L | AMLX | Chief Medical Officer | Sep 30, 2025 | Sell | $14.58 | 12,039 | $175,517.78 | 175,756 | |
| FRATES JAMES M | AMLX | Chief Financial Officer | Sep 30, 2025 | Sell | $14.65 | 10,558 | $154,650.42 | 280,430 |
Latest Amylyx Pharmaceuticals Inc. News
AMLX Breaking Stock News: Dive into AMLX Ticker-Specific Updates for Smart Investing
Compare AMLX vs Leading Stocks
See how AMLX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AMLX Amylyx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.